Cargando…
Management of aggressive fibromatosis
Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surroundin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693298/ https://www.ncbi.nlm.nih.gov/pubmed/33262835 http://dx.doi.org/10.3892/ol.2020.12304 |
_version_ | 1783614711916396544 |
---|---|
author | Zhang, Zhijun Shi, Jian Yang, Tao Liu, Tongjun Zhang, Kai |
author_facet | Zhang, Zhijun Shi, Jian Yang, Tao Liu, Tongjun Zhang, Kai |
author_sort | Zhang, Zhijun |
collection | PubMed |
description | Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surrounding organs, threatening life quality and expectancy. Although surgery, watch and wait, radiotherapy, chemotherapy, high intensity focused ultrasound, ablation techniques or several agents have all been frequently investigated for the treatment of this type of disease, none are deemed as standard therapy for high recurrence rates that have been supported by any data. The present review retrieved literature on treatment options for desmoids to summarize the latest treatment modalities and refine their efficacy, as well as their side effects, in order to provide a more comprehensive treatment reference for clinicians. |
format | Online Article Text |
id | pubmed-7693298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-76932982020-11-30 Management of aggressive fibromatosis Zhang, Zhijun Shi, Jian Yang, Tao Liu, Tongjun Zhang, Kai Oncol Lett Review Aggressive fibromatosis or desmoid tumor is a rare disease resulting from fibroblasts which do not metastasize. However, desmoid tumors belong to low-grade malignant tumors since they have high potential to infiltrate surrounding tissues, causing high local recurrence rates and may affect surrounding organs, threatening life quality and expectancy. Although surgery, watch and wait, radiotherapy, chemotherapy, high intensity focused ultrasound, ablation techniques or several agents have all been frequently investigated for the treatment of this type of disease, none are deemed as standard therapy for high recurrence rates that have been supported by any data. The present review retrieved literature on treatment options for desmoids to summarize the latest treatment modalities and refine their efficacy, as well as their side effects, in order to provide a more comprehensive treatment reference for clinicians. D.A. Spandidos 2021-01 2020-11-17 /pmc/articles/PMC7693298/ /pubmed/33262835 http://dx.doi.org/10.3892/ol.2020.12304 Text en Copyright: © Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Zhang, Zhijun Shi, Jian Yang, Tao Liu, Tongjun Zhang, Kai Management of aggressive fibromatosis |
title | Management of aggressive fibromatosis |
title_full | Management of aggressive fibromatosis |
title_fullStr | Management of aggressive fibromatosis |
title_full_unstemmed | Management of aggressive fibromatosis |
title_short | Management of aggressive fibromatosis |
title_sort | management of aggressive fibromatosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693298/ https://www.ncbi.nlm.nih.gov/pubmed/33262835 http://dx.doi.org/10.3892/ol.2020.12304 |
work_keys_str_mv | AT zhangzhijun managementofaggressivefibromatosis AT shijian managementofaggressivefibromatosis AT yangtao managementofaggressivefibromatosis AT liutongjun managementofaggressivefibromatosis AT zhangkai managementofaggressivefibromatosis |